Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
We provide a chemotherapy treatment service that offers you both choice and flexibility. Chemotherapy is the use of cytotoxic (anti-cancer) drugs to destroy cancer cells in the body by disrupting the cancer cells and preventing them from growing and dividing.
Professor Roger Taylor is a Consultant Clinical Oncologist specialising in the treatment of patients with brain tumours and lymphoma. Professor Taylor was born and educated in Swansea, and trained in Medicine at University College, Oxford and St Bartholomew’s Hospital Medical College. His oncology training was at the Royal Marsden Hospital, Royal London Hospital and Western General Hospital, Edinburgh.
He worked as a Consultant Clinical Oncologist in Leeds from 1987-2006, specialising mainly in the treatment of children with cancer. Professor Taylor returned to Wales in 2006, to work in the South West Wales Cancer Centre, Singleton Hospital, Swansea and the College of Medicine, Swansea University.
Professor Taylor provides specialist advice on proton radiotherapy in Wales, and currently is undertaking research in this field. He is author of many papers on the treatment of children with cancer, particularly brain tumours.
Oncology Vice-President, Royal College of Radiologists 2014-2016
Children’s Cancer and Leukaemia Group (CCLG).
Professor Roger Taylor does not hold a share or financial interest in the Rutherford Cancer Centres or another Rutherford Health plc company.
Professor Roger Taylor does not have a share or financial interest in equipment used at the Rutherford Cancer Centres or another Rutherford Health plc company.
Professor Roger Taylor does hold a paid advisory role(s) at the Rutherford Cancer Centres or on behalf of Rutherford Cancer Centres or Rutherford Health plc.
Get in Touch
If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or